Document Type
Conference Paper
Rights
Available under a Creative Commons Attribution Non-Commercial Share Alike 4.0 International Licence
Disciplines
1.4 CHEMICAL SCIENCES, 3. MEDICAL AND HEALTH SCIENCES, 3.4 HEALTH BIOTECHNOLOGY
Abstract
This conference paper presents an overview of the recently published FDA Process Validation Guideline for the development and manufacture of medicinal drug products. It discusses the impacts of conducting life cycle based validation activities and highlights the future challenges in meeting the ongoing 'Continued Process Validation' (CPV) expectations of the regulator. It also presents the latest information on the EU draft Process Validation Guidance - due for publication in late 2013 / 2014.
DOI
https://doi.org/10.21427/9fsc-ye52
Recommended Citation
Calnan, N. (2013). Overview of the recent FDA Process Validation Guidance for Medicinal Product Development and Manufacture. PDA Ireland Symposium : Embracing the Challenges of Lifecycle Based Validation, 7th. June 2013. doi:10.21427/9fsc-ye52
Funder
self funded
Publication Details
PDA Ireland Symposium : Embracing the Challenges of Lifecycle Based Validation